References
- Tuberculosis—United States, 1985—and the possible impact of human T-lymphotropic virus type III/lymphadenopathy-associated virus infection. MMWR Morb Mortal Wkly Rep 1986; 35(5):74–6
- Tuberculosis morbidity—United States, 1996. MMWR Morb Mortal Wkly Rep 1997; 46(30):695–700
- Barnes PF, Bloch AB, Davidson PT, et al. Tuberculosis in patients with human immunodeficiency virus infection. N Engl J Med 1991; 324(23): 1644–50
- Centers for Disease Control and Prevention. Prevention and treatment of tuberculosis among patients infected with human immunodeficiency virus: principles of therapy and revised recommendations. MMWR Morb Mortal Wkly Rep 1998; 47(RR20):1–58
- Selwyn PA, Flartel D, Lewis VA, et al. A prospective study of the risk of tuberculosis among intravenous drug users with human immunodeficiency virus infection. N Engl J Med 1989; 320(9):545–50
- Slutsker L, Castro KG, Ward JW, et al. Epidemiology of extrapulmonary tuberculosis among persons with AIDS in the United States. Clin Infect Dis 1993; 16(4):513–8
- Daley CL, Small PM, Schecter GF, et al. An outbreak of tuberculosis with accelerated progression among persons infected with the human immunodeficiency virus: an analysis using restrictionfragment-length polymorphisms. N Engl J Med 1992; 326(4):231–5
- Gordin FM, Nelson ET, Matts JP, et al. The impact of human immunodeficiency virus infection on drug-resistant tuberculosis. Am J Respir Crit Care Med 1996; 154(5):1478–83
- Weis SE, Slocum PC, Biais FX, et al. The effect of directly observed therapy on the rates of drug resistance and relapse in tuberculosis. N Engl J Med 1994; 330(7):1179–84
- Bender BS, Davidson BL, Kline R, et al. Role of the mononuclear phagocyte system in the immunopathogenesis of human immunodeficiency virus infection and the acquired immunodeficiency syndrome. Rev Infect Dis 1988; 10(6): 1142–54
- Whalen C. Copathogenicity of tuberculosis and human immunodeficiency virus disease. Clin Infect Dis (in press)
- Moreno S, Miralles P, Diaz MD, et al. Isoniazid preventive therapy in human immunodeficiency virus-infected persons: longterm effect on development of tuberculosis and survival. Arch Intern Med 1997; 157(15):1729–34
- Chaisson RE, Schecter GF, Theuer CP, et al. Tuberculosis in patients with the acquired immunodeficiency syndrome: clinical features, response to therapy, and survival. Am Rev Respir Dis 1987; 136(3):570–4
- Shafer RW, Goldberg R, Sierra M, et al. Frequency of Mycobacterium tuberculosis bacteremia in patients with tuberculosis in an area endemic for AIDS. Am Rev Respir Dis 1989; 140(6):1611–3
- Narita M, Ashkin D, Hollender ES, et al. Paradoxical worsening of tuberculosis following antiretroviral therapy in patients with AIDS. Am J Respir Crit Care Med 1998; 158(1): 157–61
- Finch D, Beaty CD. The utility of a single sputum specimen in the diagnosis of tuberculosis: comparison between HIV-infected and non-HIV-infected patients. Chest 1997; 111 (5): 1174–9
- Dalovisio JR, Montenegro-James S, Kemmerly SA, et al. Comparison of the amplified Mycobacterium tuberculosis (MTB) direct test, amplicor MTB PCR, and IS6110-PCR for detection of MTB in respiratory specimens. Clin Infect Dis 1996; 23(5):1099–106
- Telzak EE, Fazal BA, Turett GS, et al. Factors influencing time to sputum conversion among patients with smear-positive pulmonary tuberculosis. Clin Infect Dis 1998; 26(3):775–6
- Piscitelli SC, Flexner C, Minor JR, et al. Drug interactions in patients infected with human immunodeficiency virus. Clin Infect Dis 1996; 23(4):685–93
- Freiden TR, Sterling T, Pablos-Mendez A, et al. The emergence of drug-resistant tuberculosis in New York City. N Engl J Med 1993; 328(8):521–6
- Iseman MD. Treatment of multidrug-resistant tuberculosis. N Engl J Med 1993; 329(11):784–91
- Tuberculosis and human immunodeficiency virus infection: recommendations of the Advisory Committee for the Elimination of Tuberculosis (ACET). MMWR Morb Mortal Wkly Rep 1989; 38(14):236–8, 243–50